Bortezomib Accord
Authorised
This medicine is authorised for use in the European Union
bortezomib
MedicineHumanAuthorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Bortezomib Accord is a cancer medicine used to treat multiple myeloma, a blood cancer, in the following groups of patients:
- adults whose disease is getting worse after at least one other treatment and who have already had, or cannot have, blood stem-cell transplantation. In these patients, Bortezomib Accord is used either on its own or in combination with pegylated liposomal doxorubicin or dexamethasone;
- previously untreated adults who cannot have high-dose chemotherapy with blood stem-cell transplantation. In these patients, Bortezomib Accord is used in combination with melphalan and prednisone;
- previously untreated adults who are going to receive high-dose chemotherapy followed by blood stem-cell transplantation. In this group of patients, Bortezomib Accord is used in combination with dexamethasone, or with dexamethasone plus thalidomide.
Bortezomib Accord is also used to treat mantle cell lymphoma, another blood cancer, in untreated adults who cannot have blood stem-cell transplantation. For mantle cell lymphoma, Bortezomib Accord is used in combination with rituximab, cyclophosphamide, doxorubicin and prednisone.
Bortezomib Accord contains the active substance bortezomib.
Bortezomib Accord is a ‘generic medicine’. This means that Bortezomib Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Velcade.
Bortezomib Accord can only be obtained with a prescription and treatment should only be started and given under the supervision of a doctor who has experience in the use of cancer chemotherapy.
Bortezomib Accord is available as a 1 mg injection to be given into a vein or a 3.5 mg injection to be injected into a vein or under the skin. Bortezomib Accord must not be given in any other way.
The dose of Bortezomib Accord is calculated using the patient’s height and weight. When given into a vein, it is injected through a catheter (a thin sterile tube) over 3 to 5 seconds. At least 72 hours must pass between two doses of Bortezomib Accord. When injected under the skin, it is given in the thigh or abdomen (belly).
Doses of Bortezomib Accord are given with rest periods between doses, in treatment cycles of 3 to 6 weeks depending on whether Bortezomib Accord is given alone or in combination with other medicines. If a patient develops severe side effects, the treatment must be stopped, delayed or the dose adjusted.
For more information about using Bortezomib Accord, see the package leaflet or contact a doctor or pharmacist.
The active substance in Bortezomib Accord, bortezomib, is a proteasome inhibitor. It blocks the proteasome system, which breaks down proteins within cells that are no longer needed. Blocking the proteasome system causes the cell to die. Cancer cells are more sensitive to disruption by proteasome inhibitors than normal cells and, therefore, to the effects of bortezomib.
As for every medicine, the company provided studies on the quality of Bortezomib Accord. There was no need for ‘bioequivalence’ studies to investigate whether Bortezomib Accord is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because when Bortezomib Accord is given by injection into a vein, the active substance is delivered straight into the bloodstream. Also, the composition of Bortezomib Accord is the same as the reference medicine and when given by injection under the skin, the active substance in both products is expected to be absorbed in the same way.
Because Bortezomib Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicine’s.
The European Medicines Agency concluded that, in accordance with EU requirements, Bortezomib Accord has been shown to be comparable to Velcade. Therefore, the Agency’s view was that, as for Velcade, the benefit of Bortezomib Accord outweighs the identified risk and it can be authorised for use in the EU.
The company that markets Bortezomib Accord will supply educational material to healthcare professionals which explains how to calculate the dose and how to prepare and give the medicine.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bortezomib Accord have also been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Bortezomib Accord are continuously monitored. Side effects reported with Bortezomib Accord are carefully evaluated and any necessary action taken to protect patients.
Bortezomib Accord received a marketing authorisation valid throughout the EU on 20 July 2015.
Information on the reference medicine can also be found on the Agency’s website.
Product information
Latest procedure affecting product information:
VR/0000257066
31/03/2025
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Bortezomib Accord
- Active substance
- bortezomib
- International non-proprietary name (INN) or common name
- bortezomib
- Therapeutic area (MeSH)
- Multiple Myeloma
- Anatomical therapeutic chemical (ATC) code
- L01XX32
Pharmacotherapeutic group
Antineoplastic agentsTherapeutic indication
Bortezomib Accord as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.
Bortezomib Accord in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high?dose chemotherapy with haematopoietic stem cell transplantation.
Bortezomib Accord in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high?dose chemotherapy with haematopoietic stem cell transplantation.
Bortezomib Accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
News on Bortezomib Accord
This page was last updated on